• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, July 31, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Australian bee sting vaccine trial holds promise against allergic reactions

Bioengineer by Bioengineer
July 16, 2019
in Health
Reading Time: 2 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Most people have probably been stung by a bee and while it can be painful, it’s especially dangerous for the many that are at risk of suffering a life threatening allergic reaction.

Australian researchers have successfully completed a human trial on a vaccine designed to eliminate the risk of a severe allergic reaction to European honeybee stings.

The clinical trial at Flinders University and the Royal Adelaide Hospital included 27 adults with a history of allergic reactions to bee stings.

The vaccine used in the trial contained a unique sugar-based ingredient called an adjuvant, developed in Australia, which is designed to help the body neutralise the bee venom at a faster rate.

Professor Nikolai Petrovsky says the adjuvant used to enhance the bee sting vaccines has now been successfully given to over a thousand individuals across a range of different vaccines including in the current bee sting allergy trial.

“Our technology is like adding a turbocharger to a car and in this case makes the bee allergy vaccine much more powerful, allowing the immune system to better neutralise the bee venom and prevent allergic symptoms,” says Professor Petrovsky.

Associate Professor Robert Heddle, lead investigator in the trial, says the aim was to see if the Advax adjuvant would safely speed up and improve bee sting immunotherapy.

“The results of the study were very promising and confirmed the safety of this approach to improving bee sting immunotherapy.”

Dr Anthony Smith, an investigator in the trial, says while a commercial bee venom therapy is already available, it requires patients to have over 50 injections over a 3 year period to build up their immune system.

“The current treatment option for serious bee venom allergies is lengthy and cumbersome, so I hope this enhanced bee venom therapy brings about faster, but longer lasting protection to bee stings for allergic individuals.”

The Advax adjuvant which enhances the bee sting vaccines was developed in Adelaide by Vaxine Pty Ltd and has also been used to develop vaccines for seasonal and pandemic influenza, hepatitis, malaria, Alzheimers disease, cancer and other diseases.

###

Media Contact
Nikolai Petrovsky
[email protected]
http://dx.doi.org/10.1016/j.jaci.2019.03.035

Tags: Clinical TrialsEndocrinologyImmunology/Allergies/AsthmaMedicine/HealthVaccines
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Faster Team Launch Speeds Urgent Neonatal Retrievals

July 31, 2025
SPON2 Drives Osteosarcoma via M2 Macrophage Activation

SPON2 Drives Osteosarcoma via M2 Macrophage Activation

July 31, 2025

Urine Vesicle Proteomics Spotlights CD35 in Kidney Injury

July 31, 2025

Urinary Vesicle Protein CD35 Marks Sepsis Kidney Injury

July 31, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    59 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Engineered Cellular Communication Enhances CAR-T Therapy Effectiveness Against Glioblastoma

    35 shares
    Share 14 Tweet 9
  • New Measurements Elevate Hubble Tension to a Critical Crisis

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Faster Team Launch Speeds Urgent Neonatal Retrievals

SPON2 Drives Osteosarcoma via M2 Macrophage Activation

Urine Vesicle Proteomics Spotlights CD35 in Kidney Injury

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.